Approval of the XTRAC Momentum 1.0 laser system by Japan’s Ministry of Health, Labor, and Welfare marks a significant milestone for STRATA Skin Sciences. This next-generation excimer laser system is designed for the precise delivery of targeted UVB light therapy to treat specific skin areas, offering a new and advanced option for both adult and pediatric patients suffering from inflammatory skin conditions. Initially launched in the US in early 2022, the XTRAC Momentum 1.0 device will now be available in Japan through JMEC, STRATA’s long-term strategic partner and distributor.
Dr. Dolev Rafaeli, president and CEO of STRATA, expressed excitement about the regulatory approval, stating, “With this regulatory approval, we are now able to offer the Momentum device – our most advanced excimer laser – into the Japanese dermatology market. Working with JMEC, we look forward to introducing doctors and patients to the benefits of Momentum for the treatment of various dermatology conditions, such as psoriasis, eczema, and vitiligo.”
Approval Granted: XTRAC Momentum 1.0 Excimer Laser System Revolutionizes Dermatological Treatment in Japan
The XTRAC Momentum 1.0 excimer laser system allows for the precise delivery of targeted UVB light therapy, making it a valuable tool for dermatologists treating specific skin areas affected by conditions like psoriasis, eczema, and vitiligo. STRATA’s excimer devices are already in use by more than 300 hospitals and dermatology clinics across Japan, highlighting the company’s established presence in the market.
The new XTRAC Momentum 1.0 offers significant advancements over existing models, including higher power and a faster repetition rate, which enhance the efficiency and effectiveness of treatments. Additionally, the device features a new user interface and a slim design, aimed at improving the treatment experience for both clinicians and patients. These enhancements make the XTRAC Momentum 1.0 a state-of-the-art tool for dermatological care.
STRATA Skin Sciences is a medical technology company focused on developing, commercializing, and marketing products for treating dermatologic conditions. The company’s product portfolio includes the XTRAC excimer laser, the TheraClearX Acne Therapy System, and the VTRAC lamp systems. Each of these products is designed to address specific dermatological needs, providing innovative solutions for patients and healthcare providers.
Approval Secured: XTRAC Momentum 1.0 Laser System Meets Growing Demand for Advanced Dermatological Treatments in Japan
The XTRAC Momentum 1.0 laser system’s approval in Japan comes at a time when there is increasing demand for advanced dermatological treatments. Inflammatory skin conditions, such as psoriasis and eczema, affect a significant portion of the population, and effective treatments are essential for improving patients’ quality of life. The precise delivery of UVB light therapy offered by the XTRAC Momentum 1.0 is particularly beneficial for targeting affected areas without damaging surrounding healthy skin.
STRATA’s partnership with JMEC ensures that the XTRAC Momentum 1.0 will be effectively distributed and supported in the Japanese market. JMEC’s expertise and established network in the medical field will help facilitate the introduction and adoption of this advanced excimer laser system among Japanese dermatologists and their patients.
The launch of the XTRAC Momentum 1.0 in Japan also reflects STRATA’s commitment to expanding its global footprint and making its innovative dermatological treatments accessible to a wider audience. By securing regulatory approval in Japan, STRATA is positioned to meet the needs of a growing market and provide effective solutions for managing inflammatory skin conditions.
In conclusion, the FDA’s approval of the XTRAC Momentum 1.0 laser system in Japan is a significant development for STRATA Skin Sciences. The device’s advanced features, including higher power, faster repetition rate, new user interface, and slim design, make it a valuable tool for treating a range of dermatological conditions. With the support of JMEC, STRATA is well-equipped to introduce this innovative technology to the Japanese market, enhancing the treatment options available to dermatologists and their patients. This approval underscores STRATA’s dedication to advancing dermatological care and providing effective, targeted treatments for skin conditions.
Resource: Medical Device Netwok, July 23, 2024
This article has been prepared with the assistance of AI and reviewed by an editor. For more details, please refer to our Terms and Conditions. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author.